ID | 1196 |
Name of the vaccine | CVD 1208S-122 |
Microbe | Bacteria |
Disease name | Bacillary Dysentery (Shigellosis) |
Name of bacteria | Shigella genus |
Type of vaccine | Live attenuated |
Nucleic acid content | DNA |
Age | 18 to 49 years |
Description of the vaccine | Combined Shigella-ETEC vaccine. |
Name of the manufacturer | University of Maryland, Baltimore |
Name of the manufacturing country | United States |
Year of manufacture | 2023 |
Clinical Phase status | Clinical - Phase 1 |
Bacterial strain | Gram-negative bacteria. |
Efficacy | NA |
Vaccine formulation | NA |
Dosage | Single dose |
Mechanism of action | Anti-Shigella LPS IgG, anti-CFA/I antibodies production. |
Route of administration | Oral |
Indications | Prevents disease outcomes-weight loss and diarrhoea. |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | For enterotoxigenic Escherichia Coli infection. |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Single dose |
Interspecies transfer | NA |
PubMed identifier | 32257392 |
Clinical trial number | NCT04634513 |
Reference | NA |
Other name | NA |
Additional Links | NA
|